Editorial
doi: 10.1164/rccm.202003-0622ED.
Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?
Affiliations
- PMID: 32212973
- PMCID: PMC7301727
- DOI: 10.1164/rccm.202003-0622ED
Item in Clipboard
Editorial
Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?
Am J Respir Crit Care Med.
.
No abstract available
Comment on
-
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC. Am J Respir Crit Care Med. 2020. PMID: 32162970 Free PMC article. Clinical Trial.
Similar articles
-
Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect.Am J Respir Crit Care Med. 2021 Apr 1;203(7):928-929. doi: 10.1164/rccm.202012-4494LE. Am J Respir Crit Care Med. 2021. PMID: 33444516 Free PMC article. No abstract available.
-
Mortality in IMPACT: Confounded by Asthma?Am J Respir Crit Care Med. 2020 Sep 1;202(5):772-773. doi: 10.1164/rccm.202004-1159LE. Am J Respir Crit Care Med. 2020. PMID: 32396735 Free PMC article. No abstract available.
-
Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?Am J Respir Crit Care Med. 2020 Sep 1;202(5):773-774. doi: 10.1164/rccm.202004-1399LE. Am J Respir Crit Care Med. 2020. PMID: 32396736 Free PMC article. No abstract available.
-
Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease.Expert Rev Respir Med. 2018 Dec;12(12):997-1005. doi: 10.1080/17476348.2018.1548936. Epub 2018 Nov 28. Expert Rev Respir Med. 2018. PMID: 30463451 Review.
-
Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD.Med Lett Drugs Ther. 2014 Apr 14;56(1440):30-1. Med Lett Drugs Ther. 2014. PMID: 24736248 Review. No abstract available.
Cited by
-
Inhaled corticosteroid treatment and pneumonia in patients with chronic obstructive pulmonary disease - nationwide development from 1998 to 2018.Eur Clin Respir J. 2024 May 29;11(1):2359768. doi: 10.1080/20018525.2024.2359768. eCollection 2024. Eur Clin Respir J. 2024. PMID: 38817947 Free PMC article.
-
Effects of cigarette smoke exposure on pulmonary physiology, muscle strength and exercise capacity in a retrospective cohort with 30,000 subjects.PLoS One. 2021 Jun 24;16(6):e0250957. doi: 10.1371/journal.pone.0250957. eCollection 2021. PLoS One. 2021. PMID: 34166381 Free PMC article.
-
Considerations for and Mechanisms of Adjunct Therapy in COPD.J Clin Med. 2021 Mar 16;10(6):1225. doi: 10.3390/jcm10061225. J Clin Med. 2021. PMID: 33809583 Free PMC article. Review.
References
-
- Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680. - PubMed
-
- Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48:320–330. - PubMed
-
- Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. - PubMed
-
- Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–1826. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
